H.C. Wainwright lowered the firm’s price target on BioNTech (BNTX) to $145 from $150 and keeps a Buy rating on the shares. The firm says BNT327’s Phase 2 results in small-cell lung cancer appear highly promising. In addition, Peter Marks departure from the FDA doesn’t significantly change the analyst’s outlook on BioNTech.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
- Biotech Alert: Searches spiking for these stocks today
- Vaccine, gene therapy makers fall after Peter Marks resignation
- Promising Phase 2 Results and Revenue Potential Drive Buy Rating for BioNTech’s BNT327 in SCLC
- CureVac says European Patent Office dismissed BioNTech opposition
- BioNTech SE’s BNT327 Shows Promising Results in SCLC, Earning a Buy Rating from Analyst